摘要
了解和评价CA125检测对结核性胸膜炎的诊断和鉴别诊断价值。结核性胸膜炎组患者137例,肺癌组患者45例,采用ELASA法检测血清和胸水CA125水平,并和对照组比较。结果表明结核性胸膜炎组和肺癌组血清和胸水CA125水平组间无显著性差异(P>0.05),但均明显高于对照组(P<0.01)。抗结核治疗后,结核性胸膜炎组血清CA125水平降低,治疗后6个月CA125水平与对照组相比无显著性差异(P>0.05),本文提示CA125检测对结核性胸膜炎的鉴别诊断价值有限,动态观察CA125水平变化可能对预后判断有积极意义。
To study the clinical value of CA125 in differential diagnosis of tuberculous pleurisy, the serum and pleural effusion CA125 levels in 137 patients with tuberculous pleurisy ,45 patients with lung cancer and control group were detected by ELASA. The results showed that serum and pleural effusion CA125 levels in patients with tuberculous pleurisy and lung cancer had no statistically difference （ P 〉 0.05 ）, but they were significantly higher than that in control group（ P 〈0.01 ）. The serum CA125 levels in patients with tuberculous pleurisy after anti-tuberculosis treatment were decreased. After 6 months treatment,the serum CA125 levels had no statistically difference compared with control group（ P 〉0.05）. The diagnosis value of CA125 in patients with tuberculous pleurisy was limited. It may be helpful to evaluate prognosis by dynamic detecting CA125 level in patients with tuberculous pleurisy.
出处
《标记免疫分析与临床》
CAS
2009年第5期273-275,共3页
Labeled Immunoassays and Clinical Medicine
